QQ客服 官方微博 反馈留言

	Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study
	Wang, Zhao; Leng, Yun; Hou, Jian; Jin, Jie; Zhang, Mei; Ke, Xiaoyan; Jiang, Bin; Pan, Ling; Yang, Linhua; Zhou, Fang
刊名	CANCER CHEMOTHERAPY AND PHARMACOLOGY
	2017
卷号	79期号:6
关键词	Recombinant human circularly permuted TRAIL Multiple myeloma Thalidomide Dexamethasone Phase 2 clinical trials
ISSN号	0344-5704
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3540117
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Wang, Zhao,Leng, Yun,Hou, Jian,et al. Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY,2017,79(6).
APA	Wang, Zhao.,Leng, Yun.,Hou, Jian.,Jin, Jie.,Zhang, Mei.,...&Chen, Wenming.(2017).Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study.CANCER CHEMOTHERAPY AND PHARMACOLOGY,79(6).
MLA	Wang, Zhao,et al."Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study".CANCER CHEMOTHERAPY AND PHARMACOLOGY 79.6(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。